AKT1 and prostate carcinoma: Given the established role of the PI3K‐AKT‐mTOR signaling pathway in prostate cancer development, progression, and resistance to therapy, we examined the expression patterns of genes involved in this pathway.[25] Treatment with ARV‐110 and UBX‐390 for 72 h revealed that UBX‐390 exerted a more potent suppressive effect on mTOR pathway genes compared to ARV‐110, highlighting its enhanced anti‐cancer efficacy (Figure S3D, Supporting Information).